Compare LEU & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEU | IDYA |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.6B |
| IPO Year | 1998 | 2019 |
| Metric | LEU | IDYA |
|---|---|---|
| Price | $172.21 | $30.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | ★ $255.55 | $52.86 |
| AVG Volume (30 Days) | 823.2K | ★ 1.0M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ 0.45 | N/A |
| Revenue | $193,000,000.00 | ★ $218,710,000.00 |
| Revenue This Year | $3.76 | N/A |
| Revenue Next Year | $6.04 | $201.05 |
| P/E Ratio | $367.71 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $144.65 | $20.50 |
| 52 Week High | $464.00 | $39.28 |
| Indicator | LEU | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 47.76 | 57.36 |
| Support Level | $164.28 | $29.51 |
| Resistance Level | $210.85 | $31.51 |
| Average True Range (ATR) | 13.71 | 1.58 |
| MACD | 0.45 | 0.28 |
| Stochastic Oscillator | 45.74 | 80.74 |
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.